⌕
Beam Therapeutics · BEAM · Nasdaq
Tenet 61 · Solid
Compare
$20.65−1.38%At closeTenet 61 · Solid
$20.65−0.29 (−1.38%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Beam Therapeutics (BEAM) Stock

Beam Therapeutics (BEAM) closed at $20.65 on Nov 17, 2026; its Tenet Score is 61 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

23 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$20.65
Nov 17, 2026
Market cap
$2.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
20.23 – 38.26
low → high · as of close, Nov 16, 2026
Tenet Score
61/100
Solid · 340 Healthcare peers

Industry: Drugs

Beam Therapeutics Inc scores 61/100. Solid. Strongest on financial health and value, quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 61 is built from 3 of 4 pillars, from 50% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=340
61/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
76
Quality
25
Health
81
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueBQualityFHealthBGrowth—MomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.3×
Sep 30, 2026 balance sheet
P/S
14.8×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
−11%
TTM through Sep 30, 2026
Operating margin
−274.6%
fiscal 2025, before interest and tax
Net margin
−73.9%
TTM through Sep 30, 2026
Current ratio
13.00
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-1…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 91 US ETFs · top wrappers by weightSee all ETFs holding BEAM →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Beam Therapeutics in?

Beam Therapeutics is in the Healthcare sector and the Drugs industry.

What is Beam Therapeutics' Tenet Score?

Beam Therapeutics' Tenet Score is 61 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.